(Q38078423)

28 August 2017

1 reference

title

Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia (English)

1 reference

28 August 2017

Niamh Keane

1

1 reference

28 August 2017

Ciara Freeman

series ordinal

2

1 reference

28 August 2017

Ronan Swords

series ordinal

3

1 reference

28 August 2017

Francis J Giles

series ordinal

4

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Expert Review of Hematology

28 August 2017

published in

1 reference

28 August 2017

volume

6

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

9-24

1 reference

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

28 August 2017

cites work

1 reference

Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy

21 January 2018

1 reference

CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines

21 January 2018

1 reference

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines

21 January 2018

1 reference

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

21 January 2018

1 reference

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126

21 January 2018

1 reference

The activity of the lipophilic nucleoside derivatives elacytarabine and CP-4126 in a panel of tumor cell lines resistant to nucleoside analogues

21 January 2018

1 reference

General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia

21 January 2018

1 reference

21 January 2018

1 reference

Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells

21 January 2018

1 reference

Cell entry and export of nucleoside analogues

21 January 2018

1 reference

Cytarabine dose for acute myeloid leukemia

21 January 2018

1 reference

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

Genetic factors influencing cytarabine therapy

21 January 2018

1 reference

Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.

21 January 2018

1 reference

Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells.

21 January 2018

1 reference

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

21 January 2018

1 reference

In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.

21 January 2018

1 reference

Potential mechanisms of resistance to cytarabine in AML patients

21 January 2018

1 reference

FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression

21 January 2018

1 reference

Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.

21 January 2018

1 reference

Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells

21 January 2018

1 reference

Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia

21 January 2018

1 reference

Long term cultured HL-60 cells are intrinsically resistant to Ara-C through high CDA activity

21 January 2018

1 reference

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

21 January 2018

1 reference

Cytosine arabinoside influx and nucleoside transport sites in acute leukemia

21 January 2018

1 reference

Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines

21 January 2018

1 reference

Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells

21 January 2018

1 reference

Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

21 January 2018

1 reference

Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

21 January 2018

1 reference

Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia

21 January 2018

1 reference

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

Novel approaches to the treatment of acute myeloid leukemia

21 January 2018

1 reference

Older patients with acute myeloid leukemia

21 January 2018

1 reference

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?

21 January 2018

1 reference

Translating clinical trials into meaningful outcomes

21 January 2018

1 reference

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

21 January 2018

1 reference

Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.12.68

1 reference

28 August 2017

1 reference